At ESC Congress 2023 we will be 'joining forces to protect the heart' and create the future of cardiology – a future where everything is possible.
Dr Jorg Taubel will be attending in person along with Dr Julian Gilmore from the Royal Free London NHS Foundation Trust who will be presenting ‘ATTRibute-CM: acoramidis (AG10) in patients with transthyretin amyloid cardiomyopathy’
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
